SITC Cancer Immunotherapy CONNECT

Join SITC for Two Innovative Workshops on the Future of Cancer Immunotherapy

Cancer Immune Responsiveness Workshop

Immuno-Oncology Biomarkers: State of the Art

Register for both workshops and receive a 50 percent discount on the cost of the second program!


Register Now & Submit Your Research to SITC 2018

SITC 2018 registration is now open to the public. Also, submit an abstract to the 33rd Annual Meeting or presentation application to the Immune Escape program!

Check Out SITC 2018


Learn the Value of 

member-ribbon-v4.pngSee members discuss the benefits of a SITC membership in this new video.

Watch The Video


Understanding Cancer Immunotherapy – Online Activity

Designed for patients and caregivers, this interactive activity takes a closer look at the potential side effects of cancer immunotherapy. Based on the Patient Resource Guide, Understanding Cancer Immunotherapy 3rd Edition, this activity explains side effects that patients may experience while receiving cancer immunotherapy treatment and how to manage these side effects.

Register for the Class


Monitor Progress of the SITC Sparkathon

Track progress of the teams in the 2017 cohort of the SITC Sparkathon: TimIOs and the METIOR Incubator.



The Authoritative Cancer Immunotherapy Reference

SITC members who purchase Cancer Immunotherapy Principles and Practice receive a 20 percent discount and free shipping with a promo code.*

member-ribbon-v4.png*Available only when ordering from Demos Medical Publishing. Cannot be combined with any other offers.

Learn More


Explore resources and educational opportunities for cancer patients and those who advocate for them.







Track the latest advancements and educational opportunities in cancer immunotherapy and immunology.







Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.






Latest Discussions

  • ​ LUNG FORCE Expo The LUNG FORCE Expo is a program designed for healthcare providers to learn more about the latest trends, resources and research surrounding lung cancer, COPD, and other chronic lung diseases. Speakers from a variety of fields ...

  • Profile Picture


    Comments for consideration: Correction starting at line 308.  Most recently, a phase III trial comparing first line pembrolizumab plus chemotherapy (pemetrexed plus cisplatin or carboplatin) versus chemotherapy alone in 616 patients with advanced or ...

  • Profile Picture


    Comments for consideration Line 79, 216, 355-356: Suggest adding the word "unresectable stage III" to describe durvalumab indication • Line 235: Nivolumab is listed as a "fully humanized" mAb, whereas it is actually a fully human mAb. Pembrolizumab is ...

Follow the SITC Twitter Feed.


Connect with colleagues at these Upcoming Events.


Ignite the SITC Sparkathon

Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.


Learn More


The Journal & The Blog

Journal for ImmunoTherapy of Cancer

An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.

Learn More


Making Cure a Reality

It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.


Learn More